Literature DB >> 7510815

Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.

A Küpfer1, C Aeschlimann, B Wermuth, T Cerny.   

Abstract

The antineoplastic ifosfamide produces dose-dependent signs of neurotoxicity. After ifosfamide overdose in a patient, we found excessive urinary excretion of glutaric acid and sarcosine, which is compatible with glutaric aciduria type II, a defect in mitochondrial fatty acid oxidation that results from defective electron transfer to flavoproteins. We therefore used the electron-accepting drug methylene-blue as an antidote for ifosfamide encephalopathy. In one patient, ifosfamide neurotoxicity was rapidly reversed by methylene-blue 50 mg intravenously. In another patient with previous episodes of ifosfamide encephalopathy, methylene-blue was administered orally prophylactically. No symptoms of neurotoxicity were noted.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510815     DOI: 10.1016/s0140-6736(94)91839-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

Review 1.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  [Acute central nervous symptoms in oncologic patients].

Authors:  K Orlopp; I G H Schmidt-Wolf; H Urbach; U Schlegel
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

3.  Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways.

Authors:  Ali Reza A Ladiwala; Jonathan S Dordick; Peter M Tessier
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

4.  Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

Authors:  Emily Mitchell Sontag; Gregor P Lotz; Namita Agrawal; Andrew Tran; Rebecca Aron; Guocheng Yang; Mihaela Necula; Alice Lau; Steven Finkbeiner; Charles Glabe; J Lawrence Marsh; Paul J Muchowski; Leslie M Thompson
Journal:  J Neurosci       Date:  2012-08-08       Impact factor: 6.167

Review 5.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

6.  High absolute bioavailability of methylene blue given as an aqueous oral formulation.

Authors:  Ingeborg Walter-Sack; Jens Rengelshausen; Heike Oberwittler; Juergen Burhenne; Olaf Mueller; Peter Meissner; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

7.  Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients.

Authors:  H I Tahsildar; B F Remler; R J Creger; B W Cooper; S M Snodgrass; R W Tarr; H M Lazarus
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

8.  Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.

Authors:  Antonella Brunello; Umberto Basso; Elena Rossi; Micaela Stefani; Cristina Ghiotto; Dario Marino; Gino Crivellari; Silvio Monfardini
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

10.  Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?

Authors:  Bernd Kasper; Christoph Harter; Julia Meissner; Frauke Bellos; Fatime Krasniqi; Anthony D Ho; Gerlinde Egerer
Journal:  Support Care Cancer       Date:  2004-01-16       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.